Finanzas de ASP Isotopes Inc. (ASPI)ASPIASP Isotopes Inc.

ASP Isotopes Inc. (ASPI) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Specialist isotopes and related services, accounting for 81.0% of total sales, equivalent to $3.39M. Other significant revenue streams include Helium and LNG and Nuclear fuels. Understanding this composition is critical for investors evaluating how ASPI navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, ASP Isotopes Inc. maintains a gross margin of 28.89%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -667.48%, while the net margin is -663.54%. These profitability ratios, combined with a Return on Equity (ROE) of -104.60%, provide a clear picture of how effectively ASPI converts its operational activities into shareholder value.

In the context of the broader market, ASPI competes directly with industry leaders such as NUAI and IMSR. With a market capitalization of $298.19M, it holds a significant position in the sector. When comparing efficiency, ASPI's gross margin of 28.89% stands against NUAI's -8.00% and IMSR's N/A. Such benchmarking helps identify whether ASP Isotopes Inc. is trading at a premium or discount relative to its financial performance.

ASPI's financial performance shows troubling trends, with a net income of -33,585,000 in Q2 2026 and a gross margin that has decreased to 28.89%. The company has also reported significant losses over the past year, with a year-over-year change of -80.72%.